Danish investor snaps up Benchmark genetics business in £260 million deal

The acquisition is the second major aquaculture deal in as many months by the largest shareholder in Danish pharmaceutical giant Novo Nordisk.

Trond Williksen, CEO of Benchmark.
Trond Williksen, CEO of Benchmark.Photo: Robert Nedrejord
Published 25 November 2024, 08:15Updated 25 November 2024, 09:39
BenchmarkGeneticsMergers & AcquisitionsNovo HoldingsStingray Marine